

22 June 2026

ASX Announcement

Results of General Meeting

Firebrick Pharma Limited (ASX:FRE) (**Company** or **Firebrick**) advises it held a General Meeting today, at 11.00am (AEST).

The resolutions were voted in accordance with the Notice of General Meeting previously advised to the Australian Securities Exchange with all resolutions being passed on a poll.

Further information required by section 251AA(2) of the Corporations Act 2001 (Cth) is attached.

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman, Firebrick Pharma Limited.

- ENDS -

About Firebrick Pharma

Firebrick Pharma is developing and commercialising novel formulations and uses of povidone-iodine (PVP-I). Its first product, Nasodine® Nasal Spray (0.5% PVP-I), has been introduced into the United States, Singapore, and Fiji. Nasodine Nasal Spray was also recently approved for marketing in Indonesia, and the Company is pursuing approval in the Philippines and other markets. Nasodine® Throat Spray is the first follow-on product in the Nasodine range and is now available in Singapore and Fiji. Firebrick recently announced plans for a total of up to four products in the Nasodine range and expansion of sales to up to 10 markets over three years. For further information, visit firebrickpharma.com

Contacts:

Media contact:

Matthew Wright, NWR Communications
matt@nwrcommunications.com.au

Shareholder Company contact:

Kam Watson, Firebrick Pharma
investors@firebrickpharma.com

Disclosure of Proxy Votes

Firebrick Pharma Limited

General Meeting

Monday, 22 June 2026



GPO Box 5193, Sydney, NSW 2001
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)
F +61 (0)2 8583 3040 E hello@automic.com.au
ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results (if applicable)			Results
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 RATIFICATION OF PRIOR ISSUE OF PLACEMENT SHARES TO PHARMA NUTRIA N.A. INC – LISTING RULE 7.1	P	66,018,583	65,283,415 98.89%	131,947 0.20%	9,000	603,221 0.91%	69,736,357 99.81%	131,947 0.19%	9,000	Carried
2 RATIFICATION OF PRIOR ISSUE OF INCENTIVE OPTIONS TO AL MOGHADDAM	P	66,016,883	65,209,403 98.78%	204,259 0.31%	10,700	603,221 0.91%	69,662,345 99.71%	204,259 0.29%	10,700	Carried
3 RATIFICATION OF PRIOR ISSUE OF MARCH PLACEMENT SHARES – LISTING RULE 7.1	P	66,005,583	65,211,103 98.80%	191,259 0.29%	22,000	603,221 0.91%	69,664,045 99.73%	191,259 0.27%	22,000	Carried
4 RATIFICATION OF PRIOR ISSUE OF MARCH PLACEMENT SHARES – LISTING RULE 7.1A	P	66,005,583	65,211,103 98.80%	191,259 0.29%	22,000	603,221 0.91%	69,664,045 99.73%	191,259 0.27%	22,000	Carried
5 RATIFICATION OF PRIOR ISSUE OF MARCH PLACEMENT OPTIONS – LISTING RULE 7.1	P	66,005,583	65,135,203 98.68%	267,159 0.40%	22,000	603,221 0.91%	69,588,145 99.62%	267,159 0.38%	22,000	Carried
6 RATIFICATION OF PRIOR ISSUE OF BROKER OPTIONS to SP CORPORATE ADVISORY PTY LTD – LISTING RULE 7.1	P	66,016,883	65,209,403 98.78%	131,947 0.20%	10,700	675,533 1.02%	69,734,657 99.81%	131,947 0.19%	10,700	Carried

